Announcements
- Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
- Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
- Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
- Tevogen Bio Set to Join Russell 3000® Index
- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
- CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
- Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
- Tevogen Bio Reports First Quarter 2024 Financial Results
- Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
- Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
More ▼
Key statistics
On Tuesday, Tevogen Bio Holdings Inc (G28:DEU) closed at 0.64, 1.59% above its 52-week low of 0.63, set on Jun 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.67 |
---|---|
High | 0.67 |
Low | 0.64 |
Bid | 0.66 |
Offer | 0.68 |
Previous close | 0.655 |
Average volume | 0.00 |
---|---|
Shares outstanding | 166.11m |
Free float | 6.31m |
P/E (TTM) | -- |
Market cap | 118.11m USD |
EPS (TTM) | -0.0004 USD |
Data delayed at least 15 minutes, as of Jul 02 2024.
More ▼